Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
24.80
+0.53 (2.18%)
At close: Oct 29, 2026, 4:00 PM EDT
25.00
+0.20 (0.81%)
After-hours: Oct 29, 2026, 7:20 PM EDT
Viridian Therapeutics Employees
Viridian Therapeutics had 252 employees as of December 31, 2025. The number of employees increased by 109 or 76.22% compared to the previous year. That makes Viridian Therapeutics the 25,142nd largest employer in the world and 3,217th in the United States.
Employees
252
Change (1Y)
109
Growth (1Y)
76.22%
Revenue / Employee
$282,250
Profits / Employee
-$1,325,524
Market Cap
2.81B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 252 | 109 | 76.22% | 252 | 0 |
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Arcus Biosciences | 601 |
| Recursion Pharmaceuticals | 600 |
| Beam Therapeutics | 540 |
| Denali Therapeutics | 507 |
| Tarsus Pharmaceuticals | 370 |
| Nurix Therapeutics | 317 |
VRDN News
- 9 days ago - Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 - Business Wire
- 5 weeks ago - Viridian Therapeutics price target raised to $38 from $36 at RBC Capital - TheFly
- 7 weeks ago - Viridian Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 1 month ago - Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Business Wire
- 2 months ago - Viridian Therapeutics price target raised to $39 from $38 at Truist - TheFly
- 2 months ago - Viridian Therapeutics price target raised to $36 from $35 at RBC Capital - TheFly
- 2 months ago - Viridian Therapeutics reports EPS ($1.05), consensus ($1.03) - TheFly
- 2 months ago - Viridian Therapeutics sees cash runway through profitability - TheFly